Immunological Profiling of Toll-Like Receptor 3, Interferon-Alpha, and Antimicrobial Peptide LL-37 in Response to COVID-19 Infection and Vaccination in Iraqi Patients

  • Ayat S Saif College of Biotechnology, Al-Nahrain University, Baghdad, Iraq.
  • Shahlaa M Salih College of Biotechnology, Al-Nahrain University, Baghdad, Iraq.
  • Yasir W Issa Department of Anesthesia Techniques, College of Health and Medical Techniques, Middle Technical University, Baghdad, Iraq

References

Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release

syndrome in severe COVID-19: interleukin-6 receptor

antagonist tocilizumab may be the key to reduce

mortality. Int J Antimicrob Agents. 2021;55(5):105954.

[PubMed] [Google Scholar]

Mascellino MT, Di Timoteo F, De Angelis M, Oliva

A. Overview of the main anti-SARS-CoV-2 vaccines:

mechanism of action, efficacy and safety. Infect Drug

Resist. 2021;14:3459-76. [PubMed] [Google Scholar]

Published
2025-02-09
Issue
Vol. 56 No. 4 B (2024): Journal of Communicable Diseases
Section
Research Article

Copyright (c) 2024 Journal of Communicable Diseases (E-ISSN: 2581-351X & P-ISSN: 0019-5138)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.